JPH0430926B2 - - Google Patents

Info

Publication number
JPH0430926B2
JPH0430926B2 JP60034581A JP3458185A JPH0430926B2 JP H0430926 B2 JPH0430926 B2 JP H0430926B2 JP 60034581 A JP60034581 A JP 60034581A JP 3458185 A JP3458185 A JP 3458185A JP H0430926 B2 JPH0430926 B2 JP H0430926B2
Authority
JP
Japan
Prior art keywords
nasal administration
lower alkyl
powder composition
alkyl ether
calcitonin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP60034581A
Other languages
English (en)
Japanese (ja)
Other versions
JPS61194034A (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to JP60034581A priority Critical patent/JPS61194034A/ja
Priority to DE8686301317T priority patent/DE3676515D1/de
Priority to EP86301317A priority patent/EP0193372B1/en
Publication of JPS61194034A publication Critical patent/JPS61194034A/ja
Priority to MYPI87000102A priority patent/MY102422A/en
Priority to US07/132,447 priority patent/US4985242A/en
Publication of JPH0430926B2 publication Critical patent/JPH0430926B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP60034581A 1985-02-25 1985-02-25 経鼻投与用粉末状組成物 Granted JPS61194034A (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP60034581A JPS61194034A (ja) 1985-02-25 1985-02-25 経鼻投与用粉末状組成物
DE8686301317T DE3676515D1 (de) 1985-02-25 1986-02-24 Intranasal applizierbare pharmazeutische puder.
EP86301317A EP0193372B1 (en) 1985-02-25 1986-02-24 Intranasally applicable powdery pharmaceutical composition
MYPI87000102A MY102422A (en) 1985-02-25 1987-02-05 Intranasally applicable powdery pharmaceutical composition.
US07/132,447 US4985242A (en) 1985-02-25 1987-12-14 Intranasally applicable powdery pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60034581A JPS61194034A (ja) 1985-02-25 1985-02-25 経鼻投与用粉末状組成物

Publications (2)

Publication Number Publication Date
JPS61194034A JPS61194034A (ja) 1986-08-28
JPH0430926B2 true JPH0430926B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-05-25

Family

ID=12418284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60034581A Granted JPS61194034A (ja) 1985-02-25 1985-02-25 経鼻投与用粉末状組成物

Country Status (5)

Country Link
US (1) US4985242A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0193372B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS61194034A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3676515D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY102422A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601923A1 (de) * 1986-01-23 1987-07-30 Behringwerke Ag Nasal applizierbares arzneimittel, verfahren zu seiner herstellung und seine verwendung
MY102411A (en) * 1986-12-23 1992-06-17 Ciba Geigy Ag Nasal solutions
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
ZA887658B (en) * 1987-10-15 1990-06-27 Syntex Inc Intranasal administration of polypeptides in powdered form
NO179479C (no) * 1988-03-11 1996-10-16 Teikoku Seiyaku Kk Fremgangsmåte for fremstilling av et intravaginalt farmasöytisk preparat
US5260270A (en) * 1988-03-30 1993-11-09 The Johns Hopkins University Odorant-binding protein from rat
EP0360340A1 (en) * 1988-09-19 1990-03-28 Akzo N.V. Composition for nasal administration containing a peptide
IL91856A0 (en) * 1988-10-11 1990-06-10 Schiapparelli Salute Spa Pharmaceutical compositions comprising calcitonin for intranasal administration and a spray unit for the administration of the same
US5514365A (en) * 1988-10-11 1996-05-07 Schiapparelli Salute S.P.A. Pharmaceutical compositions comprising calcitonin for intranasal administration
JPH02104531A (ja) * 1988-10-14 1990-04-17 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド組成物
US5567682A (en) * 1988-12-16 1996-10-22 Advanced Peptides And Biotechnology Sciences Method of treating Alzheimer's disease
JP2704546B2 (ja) * 1989-04-04 1998-01-26 光利 太良 Ａｔｌｌ治療用吸入剤
JP2514249B2 (ja) * 1989-05-23 1996-07-10 帝人株式会社 安定化されたカルシトニン類医薬組成物
US5422340A (en) * 1989-09-01 1995-06-06 Ammann; Arthur J. TGF-βformulation for inducing bone growth
JP2911496B2 (ja) * 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
EP0432431B1 (en) * 1989-11-16 1993-06-16 PHIDEA S.p.A. Liquid pharmaceutical composition for nasal administration containing a polypeptide as active ingredient
GB9000459D0 (en) * 1990-01-09 1990-03-07 James Michael H Medicaments for treatment of airborne allergies
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
ATE113469T1 (de) * 1990-06-21 1994-11-15 Edith Dr Huland Verwendung zytokinhaltiger aerosole und zytokinhaltige aerosole selbst.
US5780012A (en) * 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
IT1242019B (it) * 1990-11-20 1994-02-02 Ripari Gero Ist Farm Biolog Composizioni farmaceutiche acquose a base di calcitonina, da somministrarsi per via nasale.
JP3179538B2 (ja) * 1990-12-11 2001-06-25 ノバルティス アクチエンゲゼルシャフト 安定なヒトカルシトニンの水性溶液
US5227152A (en) * 1991-04-09 1993-07-13 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
US5306482A (en) * 1991-04-09 1994-04-26 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
US5093105A (en) * 1991-04-09 1992-03-03 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
US5656590A (en) * 1991-05-24 1997-08-12 Amylin Pharmaceuticals, Inc. Treatment of anorexia and related states
DE4222647A1 (de) * 1991-07-15 1993-01-21 Sandoz Ag Peptid-zubereitungen
WO1993001826A1 (en) * 1991-07-19 1993-02-04 East Carolina University Method of treating asthma
US5571788A (en) * 1991-12-09 1996-11-05 Ciba-Geigy Corporation Stable calcitonin pharmaceutical compositions
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
DE69332240T2 (de) * 1992-06-12 2003-04-10 Teijin Ltd., Osaka Ultrafeines pulver zur inhalation und dessen herstellung
WO1993025193A1 (en) * 1992-06-12 1993-12-23 Teijin Limited Pharmaceutical preparation for intra-airway administration
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
DK0708657T3 (da) * 1993-06-29 2001-10-15 Ferring Bv Sammensætninger til nasal administration af desmopression
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
PT748213E (pt) 1994-03-07 2004-08-31 Nektar Therapeutics Metodos e composicoes para administracao pulmonar de insulina
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
DE69733664T3 (de) 1996-04-19 2011-04-14 Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6190699B1 (en) * 1998-05-08 2001-02-20 Nzl Corporation Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa
DE19826628C1 (de) * 1998-06-17 2000-07-20 Werner Kern Intranasale Verwendung von Insulin bei Hirnleistungsstörungen
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20030138460A1 (en) * 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
JP2003522154A (ja) * 2000-02-08 2003-07-22 アラーガン、インコーポレイテッド ボツリヌス毒素医薬組成物
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
JP4711520B2 (ja) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
EP1372611B1 (en) * 2001-03-26 2006-05-17 Novartis AG Pharmaceutical composition comprising a poorly water-soluble staurosporine, a surfactant and a water-soluble polymer
WO2003072016A2 (en) * 2001-11-19 2003-09-04 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
US20040005999A1 (en) * 2002-03-07 2004-01-08 Andreasen Kasper Huus Polyamino acid-based particle insulin preparation
WO2004084859A2 (en) 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
US20050058673A1 (en) * 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
CA2539043A1 (en) * 2003-09-17 2005-10-13 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
US9028852B2 (en) 2004-09-07 2015-05-12 3M Innovative Properties Company Cationic antiseptic compositions and methods of use
US20060051384A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Antiseptic compositions and methods of use
US8198326B2 (en) * 2004-09-07 2012-06-12 3M Innovative Properties Company Phenolic antiseptic compositions and methods of use
JP5254618B2 (ja) * 2004-10-11 2013-08-07 ナサリーズ・ピーピーエム・リミテッド 経鼻投与用組成物
GB0422582D0 (en) * 2004-10-11 2004-11-10 Nasaleze Patents Ltd Pharmaceutical compositions
US7396936B1 (en) 2004-11-09 2008-07-08 Kemia, Inc. Modulators of calcitonin and amylin receptor activity
ATE511838T1 (de) * 2005-03-10 2011-06-15 3M Innovative Properties Co Antimikrobielle zusammensetzungen mit hydroxycarboxylsäureestern
CN101137359B (zh) * 2005-03-10 2011-01-12 3M创新有限公司 治疗耳感染的方法
CA2599653A1 (en) * 2005-03-10 2006-09-21 3M Innovative Properties Company Methods of reducing microbial contamination
US7580130B2 (en) * 2005-03-23 2009-08-25 Datacolor Holding Ag Method for designing a colorimeter having integral illuminant-weighted CIE color-matching filters
JP2007084508A (ja) * 2005-09-26 2007-04-05 Shiseido Co Ltd 新規血管内皮増殖因子発現阻害剤
CA2667307C (en) 2006-10-27 2015-12-01 3M Innovative Properties Company Antimicrobial compositions comprising a c2-c5 lower alcohol, a cationic antimicrobial agent, and a fatty component containing free hydroxyl groups
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
WO2015034822A1 (en) * 2013-09-03 2015-03-12 G2B Pharma Inc. Intranasal formulation for the treatment of cardiopulmonary resuscitation (cpr), cardiac life support (cls), anaphylaxis and/or anaphylactoid reactions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3169095A (en) * 1962-10-30 1965-02-09 Rexall Drug Chemical Self-propelling powder-dispensing compositions
CA986441A (en) * 1971-10-22 1976-03-30 Aslam Khwaja Enzyme treatment
JPS6034925B2 (ja) * 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
JPS58189118A (ja) * 1982-04-30 1983-11-04 Takeda Chem Ind Ltd 経鼻投与製剤
JPS5989619A (ja) * 1982-10-05 1984-05-23 サンド・アクチエンゲゼルシヤフト カルシトニン組成物およびその用途
GB2127689B (en) * 1982-10-05 1986-07-09 Sandoz Ltd Calcitonin inhalation compositions
IL70489A0 (en) * 1982-12-29 1984-03-30 Armour Pharma Pharmaceutical compositions containing calcitonin
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物

Also Published As

Publication number Publication date
US4985242A (en) 1991-01-15
MY102422A (en) 1992-06-30
DE3676515D1 (de) 1991-02-07
EP0193372A2 (en) 1986-09-03
EP0193372B1 (en) 1990-12-27
JPS61194034A (ja) 1986-08-28
EP0193372A3 (en) 1987-07-01

Similar Documents

Publication Publication Date Title
JPH0430926B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA2179207C (en) Parathyroid hormone formulation
EP0122036B2 (en) Powdery pharmaceutical composition for nasal administration
US4690952A (en) Pharmaceutical compositions for nasal administration comprising calcitonin and an absorption-promoting substance
US7235253B2 (en) Powder containing physiologically active peptide
CA2375914A1 (en) Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
JPH05963A (ja) ポリペプチド類組成物
JPH10501519A (ja) インシュリンを肺に送給できる方法および組成物
JPH05508616A (ja) 治療用エアロゾル剤
JP2002363097A (ja) 安定化された凍結乾燥型医薬組成物
JPS632932A (ja) 経鼻投与用粉末状組成物
JPS60224616A (ja) 経鼻投与用組成物
EP0938902A1 (en) Human growth hormone-containing aqueous pharamceutical composition
GB2193891A (en) Nasal pharmaceutical compositions containing octreotide
JP2505430B2 (ja) 塩基性アミノ酸を含有する経鼻投与用粉末状組成物
JPH02111A (ja) 経鼻投与用生理活性ペプチド製剤
JPH0338255B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPH0441421A (ja) 肺吸収組成物
JPH0480008B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPH05170664A (ja) 安定なペプチド医薬組成物
JPH0688898B2 (ja) アスコルビン酸類を含有する経鼻投与用粉末状組成物
JPH09309843A (ja) ヒアルロン酸含有経肺投与用製剤
JPS63303931A (ja) 経鼻投与用成長ホルモン放出活性物質製剤
JPH0578258A (ja) 安定なカルシトニン医薬組成物及びその製造法
CN114432432A (zh) 一种吸入制剂

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term